This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Brodsky, S. Articles by Winaver, J. Search for Related Content PubMed PubMed Citation Articles by Brodsky, S. Articles by Winaver, J. Pubmed/NCBI databases Compound via MeSH Substance via MeSH Hazardous Substances DB ENALAPRIL MALEATE SODIUM THIOPHENE Medline Plus Health Information Heart Failure

(Hypertension. 1998;32:746-752.)
© 1998 American Heart Association, Inc.

Scientific Contributions

Effects of Eprosartan on Renal Function and Cardiac Hypertrophy in Rats With Experimental Heart Failure

Sergey Brodsky; Konstantin Gurbanov; Zaid Abassi; Aaron Hoffman; Robert R. Ruffolo, Jr; Giora Z. Feuerstein; ; Joseph Winaver

From the Department of Physiology and Biophysics, Faculty of Medicine, Technion-Israel Institute of Technology, Haifa, Israel (S.B., K.G., Z.A., A.H., J.W.), and Department of Cardiovascular Pharmacology, SmithKline Beecham Pharmaceuticals, King of Prussia, Pa (R.R.R., G.Z.F.).

Correspondence to Joseph Winaver, MD, Department of Physiology and Biophysics, The Bruce Rappaport Faculty of Medicine, Technion-Israel Institute of Technology, Efron St 1, POB 9649, Haifa 31096, Israel. E-mail winaver{at}tx.technion.ac.il

Abstract—Activation of the renin-angiotensin system may contribute to the derangement in renal and cardiac function in congestive heart failure. The present study evaluated the effects of eprosartan, a selective angiotensin II receptor antagonist, on renal hemodynamic and excretory parameters and on the development of cardiac hypertrophy in rats with aortocaval fistula, an experimental model of congestive heart failure. Infusion of eprosartan (1.0 mg/kg) in rats with aortocaval fistula produced a significant increase (+34%) in total renal blood flow and a sustained decrease (-33%) in the calculated renal vascular resistance. These effects on renal hemodynamics were more pronounced than those observed in sham-operated control rats and occurred despite a significant fall (-12%) in mean arterial blood pressure. Moreover, eprosartan caused a preferential increase in renal cortical blood perfusion and significantly increased glomerular filtration in rats with congestive heart failure. Chronic administration of eprosartan (5.0 mg/kg per day for 7 days through osmotic minipumps inserted intraperitoneally on the day of operation) resulted in a significant enhancement of urinary sodium excretion compared with nontreated rats with heart failure. Moreover, administration of eprosartan to salt-retaining rats with congestive heart failure resulted in a progressive increase and ultimate recovery in urinary sodium excretion. Finally, early treatment with eprosartan blocked the development of cardiac hypertrophy in rats with aortocaval fistula to a larger extent than the angiotensin-converting enzyme inhibitor enalapril. These findings emphasize the importance of angiotensin II in mediating the impairment in renal function and induction of cardiac hypertrophy in heart failure and further suggest that angiotensin II receptor blockade may be a useful treatment of these consequences in severe cardiac failure.

Key Words: angiotensin II • angiotensin antagonist • fistula, aortocaval • hypertrophy • renal circulation • hemodynamics • rats

This article has been cited by other articles:

				I. Rubinstein, Z. Abassi, F. Milman, E. Ovcharenko, R. Coleman, J. Winaver, and O. S. Better Hyperbaric oxygen treatment improves GFR in rats with ischaemia/reperfusion renal injury: a possible role for the antioxidant/oxidant balance in the ischaemic kidney Nephrol. Dial. Transplant., September 17, 2008; (2008) gfn511v1. [Abstract] [Full Text] [PDF]

				B. Bishara, H. Shiekh, T. Karram, I. Rubinstein, Z. S. Azzam, N. Abu-Saleh, S. Nitecki, J. Winaver, A. Hoffman, and Z. A. Abassi Effects of Novel Vasopressin Receptor Antagonists on Renal Function and Cardiac Hypertrophy in Rats with Experimental Congestive Heart Failure J. Pharmacol. Exp. Ther., August 1, 2008; 326(2): 414 - 422. [Abstract] [Full Text] [PDF]

				Z. S. Azzam, Y. Adir, L. Welch, J. Chen, J. Winaver, P. Factor, N. Krivoy, A. Hoffman, J. I. Sznajder, and Z. Abassi Alveolar fluid reabsorption is increased in rats with compensated heart failure Am J Physiol Lung Cell Mol Physiol, November 1, 2006; 291(5): L1094 - L1100. [Abstract] [Full Text] [PDF]

				E. Ovcharenko, Z. Abassi, I. Rubinstein, A. Kaballa, A. Hoffman, and J. Winaver Renal effects of human urotensin-II in rats with experimental congestive heart failure Nephrol. Dial. Transplant., May 1, 2006; 21(5): 1205 - 1211. [Abstract] [Full Text] [PDF]

				J. Winaver, E. Ovcharenko, I. Rubinstein, K. Gurbanov, P. Pollesello, B. Bishara, A. Hoffman, and Z. Abassi Involvement of Rho kinase pathway in the mechanism of renal vasoconstriction and cardiac hypertrophy in rats with experimental heart failure Am J Physiol Heart Circ Physiol, May 1, 2006; 290(5): H2007 - H2014. [Abstract] [Full Text] [PDF]

				T. Karram, A. Abbasi, S. Keidar, E. Golomb, I. Hochberg, J. Winaver, A. Hoffman, and Z. Abassi Effects of spironolactone and eprosartan on cardiac remodeling and angiotensin-converting enzyme isoforms in rats with experimental heart failure Am J Physiol Heart Circ Physiol, October 1, 2005; 289(4): H1351 - H1358. [Abstract] [Full Text] [PDF]

				Z. A. Abassi, A. Yahia, S. Zeid, T. Karram, E. Golomb, J. Winaver, and A. Hoffman Cardiac and renal effects of omapatrilat, a vasopeptidase inhibitor, in rats with experimental congestive heart failure Am J Physiol Heart Circ Physiol, February 1, 2005; 288(2): H722 - H728. [Abstract] [Full Text] [PDF]

				G. M. Bialik, Z. A. Abassi, I. Hammel, J. Winaver, and D. Lewinson Evaluation of Atrial Natriuretic Peptide and Brain Natriuretic Peptide in Atrial Granules of Rats with Experimental Congestive Heart Failure J. Histochem. Cytochem., October 1, 2001; 49(10): 1293 - 1300. [Abstract] [Full Text] [PDF]

				Z. A. Abassi, S. Brodsky, T. Karram, I. Dobkin, J. Winaver, and A. Hoffman Temporal changes in natriuretic and antinatriuretic systems after closure of a large arteriovenous fistula Cardiovasc Res, August 15, 2001; 51(3): 567 - 576. [Abstract] [Full Text] [PDF]

				H. Shigematsu, Y. Hirooka, K. Eshima, M. Shihara, T. Tagawa, and A. Takeshita Endogenous angiotensin II in the NTS contributes to sympathetic activation in rats with aortocaval shunt Am J Physiol Regulatory Integrative Comp Physiol, June 1, 2001; 280(6): R1665 - R1673. [Abstract] [Full Text] [PDF]

				F. C. Barone, R. W. Coatney, S. Chandra, S. K. Sarkar, A. H. Nelson, L. C. Contino, D. P. Brooks, W. G. Campbell Jr., E. H. Ohlstein, and R. N. Willette Eprosartan reduces cardiac hypertrophy, protects heart and kidney, and prevents early mortality in severely hypertensive stroke-prone rats Cardiovasc Res, June 1, 2001; 50(3): 525 - 537. [Abstract] [Full Text] [PDF]

				T. M. Behr, X. Wang, N. Aiyar, R. W. Coatney, X. Li, P. Koster, C. E. Angermann, E. Ohlstein, G. Z. Feuerstein, and J. Winaver Monocyte Chemoattractant Protein-1 is Upregulated in Rats With Volume-Overload Congestive Heart Failure Circulation, September 12, 2000; 102(11): 1315 - 1322. [Abstract] [Full Text] [PDF]

				T. Tamura, S. Said, J. Harris, W. Lu, and A. M. Gerdes Reverse Remodeling of Cardiac Myocyte Hypertrophy in Hypertension and Failure by Targeting of the Renin-Angiotensin System Circulation, July 11, 2000; 102(2): 253 - 259. [Abstract] [Full Text] [PDF]